ForPatients
*by Roche*

Neovascular Age-related Macular Degeneration

# A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Recruiting | 1 Countries | NCT05562947 YR42983 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

**Hoffmann-La Roche**
Sponsor

**Phase 3**
Phase

**NCT05562947 YR42983**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | >=50 Years & <= 80 Years | No |